The investment supports the clinical development of two nove…
Born from the Foundation Fighting Blindness, the RD (Retinal Degeneration) Fund was created to help accelerate life-changing outcomes for people with retinal degenerations through direct mission related investments in therapeutic companies. The mission of the Foundation Fighting Blindness is to rapidly drive the research that will lead to preventions, treatments and cures for retinal degenerative diseases – including retinitis pigmentosa, age-related macular degeneration, Usher syndrome and the entire spectrum of retinal degenerative diseases. Together, these blinding conditions affect more than 200 million people throughout the world.
The RD Fund is changing how the world treats blinding retinal diseases.
Click here to download the January 2022 Outcomes & Outlook Report.
IN THE NEWS
12/28/2022
Opus Genetics Announces Acquisition of the Rights to Two Gene Thera…
Opus to advance preclinical development programs for BEST1- …
12/01/2022
SparingVision's lead asset SPVN06 clears IND application in the US…
SparingVision set to advance into the clinic with breakthrou…
12/01/2022
Opus Genetics Receives FDA Clearance of IND Application for OPGx-00…
OPGx-001 is Opus’ first program to enter clinical evaluation…
11/10/2022
Foundation Launching its Largest Natural History Study to Date for…
Uni-Rare Study will improve clinical understanding of more I…
11/08/2022
Nacuity Pharmaceuticals Expands Board of Directors with Appointment…
Managing director of the Retinal Degeneration Fund joins boa…
11/08/2022
Atsena Therapeutics Expands Leadership Team with Appointment of Lis…
Biotech leader brings extensive experience in finance, busin…
10/12/2022
Ascidian Therapeutics Launches to Rewrite RNA
ATP incubated and built Ascidian with $50 million in Series …
10/03/2022
Atsena Therapeutics Announces Positive Results from Phase I/II Clin…
ATSN-101 demonstrated clinically meaningful improvements in …
09/27/2022
Opus Genetics Expands Board of Directors with Appointment of Global…
RESEARCH TRIANGLE PARK, N.C., Sept. 27, 2022 (GLOBE NEWSWIRE…
09/15/2022
RD Fund Participates in a €75 Million Series B for SparingVision
Proceeds to fund first, in-human trials of breakthrough gene…
08/12/2022
ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Pa…
- In line with corporate strategy update in April, ProQR to f…